Notably, MB-102 (NCT04109482 and NCT02159495) and UniCAR02-T (NCT04230265) are targeting CD123-positive hematological malignancies, including BPDCN [25,54,55] (Figure 3). Here, IL3RA is linked to CD4+/CD56+ hematodermic neoplasm.